All Cardiovascular disease articles
-
Working party guideline/algorithmBest practice treatment and management of patients with type 2 diabetes, cardiovascular disease, and heart failure
This management algorithm was developed by a multidisciplinary expert panel: Javaid et al with the support of an educational grant from AstraZeneca. Information intended for UK healthcare professionals.
-
PHE/DH/DWP guideline
NHS statin intolerance pathway
A Guidelines summary covering the definition, classification, and management of statin intolerance
-
News
Soluble paracetamol linked to increased risk of cardiovascular disease and death
There may be a link between salt-containing dissolvable paracetamol tablets and an increased risk of cardiovascular disease, new research suggests
-
eLearning module
Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants—a patient case study
This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto▼(rivaroxaban)
PP-XAR-GB-2415 January 2022 -
News
Hidden burden of severe aortic stenosis far exceeds current NHS capacity
A new analysis of the data on severe aortic stenosis reveals that the potential demand from undiagnosed patients exceeds NHS capacity to screen or treat the disease
-
NHS guideline
NHS lipid management pathway
This Guidelines summary covers key recommendations from national guidance on lipid management for the primary and secondary prevention of cardiovascular disease
-
NICE guideline
NICE heart valve disease guideline
Covering investigation and management of heart valve disease in adults
-
News
Heart failure could be diagnosed earlier in primary care
New research suggests that three-quarters of patients with heart failure could be identified earlier with increased natriuretic peptide testing in primary care
-
NICE guideline
NICE CVD guideline
A concise summary of NICE's evidence-based clinical guideline on lipid modification for the prevention of cardiovascular disease
-
News
NICE publishes an update to guidance on chronic kidney disease
Updated NICE guideline covers investigation and treatment of chronic kidney disease and associated disorders
-
Independent professional body guideline
CaReMeUK cardiovascular risk optimisation algorithm
A guide for non-diabetes specialist physicians and primary care teams for cardiovascular risk optimisation in patients with type 2 diabetes and atherosclerotic cardiovascular disease
-
Independent professional body guideline
HEART UK Managing hyperlipidaemia and COVID-19
A summary of collated current evidence surrounding the safety of lipid-lowering medications in patients who have COVID-19
-
NICE guideline
NICE FH guideline
A summary of NICE guidance on the identification and management of familial hypercholesterolaemia, which includes diagnostic criteria and when to refer
-
SIGN guideline
SIGN cardiac arrhythmias guideline
Read the latest recommendations on the management of atrial fibrillation and ventricular arrhythmias in acute coronary syndrome, coronary heart disease, and left-ventricular dysfunction as well as arrhythmias associated with cardiac arrest and coronary artery bypass graft.
-
Working party guideline/algorithm
Stable peripheral arterial disease guideline
This guideline was developed by a multidisciplinary expert panel: Begg A et al with the support of a grant from Bayer plc.
-
Working party guideline/algorithm
Stable coronary artery disease guideline
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.
-
NICE guideline
NICE chronic heart failure guideline
This summary of the NICE heart failure guideline covers management and monitoring treatment. Includes algorithms on diagnosis and therapies.
-
SIGN guideline
SIGN stable angina guideline
This summary includes management algorithms for patients with suspected angina, and patients with a definite diagnosis of stable angina.
-
SIGN guideline
SIGN CVD guideline
This summary covers estimation of cardiovascular event risk, lifestyle interventions, and pharmacological therapy.
-
News
SIGN releases updated guidance on cardiovascular disease
The Scottish Intercollegiate Guidelines Network (SIGN) has published SIGN 149 Risk estimation and the prevention of cardiovascular disease and SIGN 150 Cardiac rehabilitation . SIGN 149 Risk estimation and the prevention of cardiovascular disease : It is estimated that in 2015 cardiovascular disease (CVD) caused more ...
